CEO Karlheinz Gast resigns for personal reasons – Bruno Wohlschlegel takes over as successor – Biotech Investments

APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons – Bruno Wohlschlegel takes over as successor

Monheim, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, Karl-Heinz Gast, has informed the Supervisory Board today that he is resigning from his office for personal reasons with immediate effect and that he is leaving the Executive Board.

The Supervisory Board received and accepted Mr. Gast’s resignation at its extraordinary meeting today. The service agreement with Mr. Gast will be canceled.

At the same time, the Supervisory Board appointed Bruno Wohlschlegel as a member of the Executive Board and as CEO for a period of 2 years with an effective date of 1 September 2023. Until then, Executive Board member Thomas Milz will head the company alone.

Mr. Wohlschlegel (56) brings more than 26 years of experience in the pharmaceutical industry. He was Managing Director of Merck Serono GmbH until 2021 and responsible for the European business of Merck KGaA before that. Mr. Wohlschlegel is a recognized leader with an outstanding strategic and operational track record.

The Supervisory Board of APONTIS PHARMA accepts Mr. Gast’s personal decision. “On behalf of the company, I would like to thank the previous CEO for his work over the past years,” said Dr. Matthias Wiedenfels, Chairman of the Supervisory Board. “Without Mr. Gast’s groundwork, APONTIS PHARMA would not exist and the Single Pill business to the patient’s best benefit as it stands today probably neither. We wish Mr. Gast all the best.”

“The change will not have negative implications for the operational business,” Dr. Wiedenfels continued. “The Supervisory Board is taking this opportunity to bring forward the leadership change that was originally scheduled to take place anyway after the end of the appointment period. Thanks to the focused work of the Personnel Committee, we were able to recruit an outstanding top manager at short notice. With Bruno Wohlschlegel, we are able to put together the best team for the company with a strong future.”

“I am very much looking forward to the task that the Supervisory Board has entrusted to me,” said Bruno Wohlschlegel, new designated CEO of APONTIS PHARMA AG. “I have been active in this market for more than 26 years, know the prescription landscape and APONTIS PHARMA’S products well, and look forward to working with the employees. The first priority for me is to consistently and reliably align the company with the growth strategy according to commercial and operational best practices.”

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. APONTIS PHARMA develops, promotes, and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS PHARMA successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe’s leading pharmaceutical and chemical regions. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 25,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.com

APONTIS PHARMA Press Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330